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Abstract
Background: Outcomes data regarding advanced synovial sarcoma (SS) and myx-
oid/round cell liposarcoma (MRCL) are limited, consisting primarily of retrospective 
series and post hoc analyses of clinical trials.
Methods: In this multi-center retrospective study, data were abstracted from the 
medical records of 350 patients from nine sarcoma centers throughout the United 
States and combined into a registry. Patients with advanced/unresectable or meta-
static SS (n = 249) or MRCL (n = 101) who received first-line systemic anticancer 
therapy and had records of tumor imaging were included. Overall survival (OS), 
time to next treatment, time to distant metastasis, and progression-free survival (PFS) 
were evaluated using the Kaplan-Meier method and Cox regression.
Results: At start of first-line systemic anticancer therapy, 92.4% of patients with 
SS and 91.1% of patients with MRCL had metastatic lesions. However, 74.7% of 
patients with SS and 72.3% of patients with MRCL had ≥2 lines of systemic therapy. 
Median OS and median PFS from first-line therapy for SS was 24.7 months (95% CI, 
20.9-29.4) and 7.5 months, respectively (95% CI, 6.4-8.4). Median OS and median 
PFS from start of first-line therapy for MRCL was 29.9 months (95% CI, 27-44.6) 
and 8.9 months (95% CI 4.5-12.0).
Conclusions: To the best of our knowledge, this is the largest retrospective study of 
patients with SS and MRCL. It provides an analysis of real-world clinical outcomes 
among patients treated at major sarcoma cancer centers and could inform treatment 
decisions and design of clinical trials. In general, the survival outcomes for this se-
lected population appear more favorable than in published literature.
K E Y W O R D S
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1 |  INTRODUCTION
Synovial sarcoma (SS) and myxoid/round cell liposarcoma 
(MRCL) are the two most common translocation-driven soft 
tissue sarcoma subtypes and share a number of important clin-
ical and biologic features.1 They have a similar annual inci-
dence rate of 800-1000 cases per year.2,3 Both SS and MRCL 
occur most commonly in young adults and are often initially 
sensitive to chemotherapy. However, both diseases can be 
aggressive and have dismal outcomes in the refractory met-
astatic settings.4-7 Overall, the median overall survival (OS) 
for soft tissue sarcoma is 4-18.5 months for patients treated 
with chemotherapy.8 In an analysis of seven randomized tri-
als on first-line chemotherapy by the European Organisation 
for Research and Treatment of Cancer, the median survival 
was 51 weeks for advanced soft tissue sarcoma and the over-
all response rate was 26%.9 For newly diagnosed patients 
with advanced disease, a median survival of 22 months and 
a response rate of 58.6% to doxorubicin plus ifosfamide were 
reported.10 In a recent study comparing doxorubicin plus 
evofosfamide to doxorubicin that enrolled 640 patients, the 
OS was 18.4  months vs 19  months, respectively, and pro-
gression-free survival (PFS) was 6.3 months vs 6 months.11 
In a separate analysis of 15 randomized clinical trials, the 
response to chemotherapy was 27.8% for patients with SS 
vs 18.8% for all patients, with an OS of 15.0 months for SS 
vs 11.7  months for all subjects and PFS of 6.3  months vs 
3.7 months, respectively.5 For SS, the time to next treatment 
after progression on first-line therapy was 8.3 months, with 
an OS at time of starting second-line treatment of 18.6%.4
The natural history of MRCL is less well defined in the 
literature. In a trial of trabectedin for metastatic liposarcoma 
or leiomyosarcoma, the PFS for patients treated with trabec-
tedin was 4.2 months vs 1.5 months for dacarbazine and the 
OS was 12.4 months vs 12.9 months. In this study, only 11% 
of enrolled subjects were of the MRCL histologic subtype.12 
In another Phase 3 trial, the OS was 13.5 months for eribulin 
vs 11.5 months for dacarbazine, and PFS was 2.6 months for 
both the eribulin and dacarbazine arms.13 However, only 12% 
of patients had MRCL.
Recently, the biology of these two cancers has raised in-
terest in the development of tumor-specific research in SS 
and MRCL. Emerging data has revealed key insights into the 
biology of the translocations that drive these tumors, sug-
gesting that molecularly targeted approaches and epigenetic 
modifications could be promising treatment strategies.14-16 
Immunotherapy also may be a potential treatment for these 
cancers, since they both have high rates of the target protein 
NY-ESO-1.17
Synovial sarcoma and MRCL are unique among malig-
nancies in their confirmed high incidence of NY-ESO-1 ho-
mogeneous expression (>80%) patterns. Both SS and MRCL 
also appear to have immune microenvironments with few 
infiltrating T cells and low levels of antigen presentation pro-
teins.18,19 As a result of these findings, there is significant 
interest in evaluating the expression of cytokines and other 
immunomodulators in these cancers.
A review of the literature regarding SS and MRCL clini-
cal outcomes identified only retrospective series and post hoc 
subgroup analyses from randomized clinical trials.3-8,10,20,21 
In SS and MRCL, there is an unmet need to better understand 
clinical outcomes to inform clinical management of these 
sarcomas and design prospective clinical studies.3,7 In clini-
cal trial data sets specific to SS and/or MRCL, the quality of 
data is limited by the heterogeneity of patients, sparse stag-
ing information, and varying length of survival follow-up, 
which limits the generalizability of results.3-8,10,20,21 Recent 
studies have reported the need for improved understanding 
of the tumor biology, pattern of spread, prognostic factors, 
and treatments that lead to improved outcomes in SS and 
MRCL.3,6,7
The objective of this multi-center, retrospective registry 
study was to document the clinical outcomes of patients with 
advanced SS or MRCL treated with at least 1 line of systemic 
anticancer therapy using data from real world experience. 
These data could then inform the design of trials with novel 
agents in the future.
2 |  STUDY METHODS
2.1 | Patient identification and data 
abstraction
Data were abstracted from medical records of 350 patients 
diagnosed with either SS or MRCL and treated for locally 
advanced/unresectable or metastatic disease at nine United 
States cancer centers that specialize in management of soft 
tissue sarcoma. The information was recorded so that patients 
could not be identified directly or through identifiers linked 
to the patients. As such, Exemption 45 Code of Federal 
Regulations 46.101(b)(4) applies to this study. This study 
was eligible for HIPAA waiver and expedited Institutional 
Review Board review. The Institutional Review Boards at the 
participating study sites approved this study.
Each center identified patients diagnosed with SS or MRCL 
for eligibility review. Patients diagnosed with advanced SS or 
MRCL and treated with at least 1 line of systemic anticancer 
therapy for locally advanced/unresectable or metastatic disease 
between 1 January 2005 and 31 December 2015 were eligi-
ble for inclusion in the study. The diagnosis of SS and MRCL 
for each patient was required to be validated by a documented 
signed pathology report detailing the diagnosis. Surgical pa-
thology notes and/or radiology reports were used to determine 
the disease status. Tumors were considered locally advanced or 
unresectable if the resection margin of the tumor had evidence 
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of positive tumor in the surgical margin or if the primary tumor 
was deemed inoperable per a source-verified clinic note doc-
umenting that the tumor was not operable with no evidence 
of distant metastasis. Stage IV or metastatic disease was de-
termined using evidence from either a radiology report that 
documented at least one or more distant metastatic lesions or 
through clinic notes that stated that the tumor was metastatic 
prior to the start of systemic anti-cancer therapy. Patients were 
excluded from the study if they had a history of another can-
cer within 2 years prior to their SS or MRCL diagnosis, except 
excised in situ carcinoma or non-melanoma cutaneous malig-
nancies. Patients without clinical records of tumor imaging or 
systemic anticancer therapy administration were excluded.
All data on patients who met eligibility criteria were an-
alyzed for clinical outcomes after each line of systemic an-
ticancer therapy. The primary endpoint was OS, which was 
defined as the time from date of first administration of the 
first line of systemic anticancer therapy until death due to any 
cause. Patients without death were censored at last known 
alive date. PFS was defined as the time from date of first 
administration of each line of systemic anticancer therapy to 
progression or death. Patients without progression or death 
were censored at the start date of the next line of systemic 
anticancer therapy, or if there was no additional systemic an-
ticancer therapy administered, the patients were censored at 
the end date of the current line of systemic anticancer therapy.
Secondary endpoints were time to next treatment (TTNT), 
time to distant metastasis (TTDM), and PFS. TTNT was de-
fined as the time from date of first administration of each line 
of systemic anticancer therapy to the next subsequent sys-
temic anticancer therapy, and patients who did not have fur-
ther therapy were censored at last known alive date. TTDM 
was defined as the time from first administration of systemic 
anticancer therapy to a new distant organ with evidence of a 
new lesion. Patients without distant metastasis were censored 
at the start date of the next line of systemic anticancer therapy 
or censored at the end date of the current line of systemic an-
ticancer therapy if there were no additional lines of systemic 
anticancer therapy.
Exploratory endpoints were prognostic factors, clinical 
benefit rate (complete response + partial response + stable 
disease), pattern of tumor recurrence, and use of supportive 
care.
The tumor response for each line of systemic anti-can-
cer therapy was determined using the treating oncologist's 
recorded assessment by clinical exam and/or radiographic 
imaging, such as computed tomography and magnetic reso-
nance imaging. The following information and assessments 
for each patient were included in the registry data: demo-
graphics, date of birth, sex, race, performance status, tumor 
histology, medical history, tumor history, and clinical visits.
The data analysis was conducted from March 2017 to 
December 2017 using SAS 9.4. Kaplan-Meier methodology 
was used to evaluate the data for clinical outcomes (OS, PFS, 
TTNT, TTDM). Cox regression was used to estimate hazard 
ratios. Forest plots were generated to evaluate the impact of 
baseline characteristics on clinical outcomes.
3 |  RESULTS
3.1 | Patient demographics
There were 249 patients with SS and 101 patients with MRCL 
who received first-line systemic anticancer therapy included 
in the study. The median age at diagnosis for SS and MRCL 
was 40 years (range 19, 86) and 50 years (range 27, 82), re-
spectively, and percent male for SS and MRCL was 58.2% 
and 67.3%, respectively.
The stage at diagnosis for patients with SS was 2.0% stage 
I, 14.5% stage II, 39.0% stage III, and 24.5% stage IV. Among 
patients with SS, 85.1% had evidence of metastatic disease at 
start of first-line systemic anticancer therapy, and the rest had 
locally advanced/unresectable disease. The stage at diagnosis 
for patients with MRCL was 2.0% stage I, 21.8% stage II, 
29.7% stage III, and 17.8% stage IV. Among patients with 
MRCL, 91.1% had evidence of metastatic disease at start of 
first-line systemic anticancer therapy, and the rest had locally 
advanced/unresectable disease.
The 249 patients with SS all had ≥1 line of systemic an-
ticancer therapy since this was required for study entry, and 
74.7% had ≥2 lines of therapy (Figure 1). The most common 
first-line and second-line systemic anticancer therapy for 
SS was doxorubicin plus ifosfamide and single agent ifos-
famide, respectively. Many patients with SS had treatment 
other than systemic anticancer therapy during any line of 
therapy, including metastectomy (n = 114 [45.8%]), radiation 
(n = 52 [20.9%]), radiofrequency ablation (n = 7 [2.8%]), and 
cryoablation (n = 2 [0.8%]).
The 101 patients with MRCL all had ≥1 line of systemic 
anticancer therapy required for study entry, and 72.3% had ≥2 
lines of therapy (Figure 1). The most common first-line and 
second-line systemic anticancer therapies for patients with 
MRCL were doxorubicin plus ifosfamide and other single 
agents, respectively. The use of treatment other than systemic 
anticancer therapy for the patients with MRCL during any 
line of therapy included metastectomy (n = 53 [52.5%]) and 
radiation therapy (n = 26 [25.7%]). No patient with MRCL 
received radiofrequency ablation or cryotherapy.
3.2 | Patient outcomes
Overall survival, PFS, and other clinical outcomes (TTNT 
and TTDM) for patients with SS or MRCL from start of first-
line systemic anticancer therapy are listed in Table  1. The 
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median 12-month OS rates for patients with SS and MRCL 
were 84.6% (95% CI, 79.3-88.6) and 84.6% (95% CI, 75.7-
90.4), respectively, and the median 12-month PFS rates were 
26.3% (95% CI, 20.2-32.7) for patients with SS and 37.5% 
(95% CI, 27.4-47.6) for patients with MRCL.
The median OS for the 165 patients with SS from start 
of second-line systemic anticancer therapy was 16.0 months 
(95% CI, 13.5-18.9) and the median PFS for these patients 
was 3.9 months (95% CI, 3.4-5.1). The median OS for the 73 
patients with MRCL from the start of second-line systemic 
anticancer therapy was 25.7 months (95% CI, 19.2-32.1) and 
the PFS for these patients was 3.5 months (95% CI, 2.7-5.5).
Forest plots of OS outcomes from first-line systemic anti-
cancer therapy for SS and MRCL patients enrolled in the trial 
by baseline characteristics and tumor history are presented in 
Figures 2 and 3.
For patients with SS, the most frequent site of recurrence 
after first- and second-line systemic anticancer therapy was 
F I G U R E  1  Anticancer therapy (top 
5 therapies vs. other therapy) in first- and 
second line. A, Synovial sarcoma: anticancer 
therapy (top 5 vs other) in first line. In first 
line, the single agents included in "Other 
single agent systemic therapy" category 
are atezolizumab, cisplatin, gemcitabine, 
interferon gamma, ontuxizumab, other 
hormone antagonists and related agents, 
pazopanib, and trabectedin. B, Myxoid/
round cell liposarcoma: anticancer therapy 
(top 5 vs other) in first line. In first line, the 
single agents included in "Other single agent 
systemic therapy" category are dacarbazine, 
gemcitabine, monoclonal antibodies, other 
vaccines, oxaliplatin, paclitaxel, pazopanib, 
ridaforolimus, temozolomide, and vaccines. 
C, Synovial sarcoma: anticancer therapy 
(top 5 vs other) in second line. In second 
line, the single agents included in "Other 
single agent systemic therapy" category 
are antilymphocyte immunoglobulin, 
atezolizumab, dacarbazine, doxorubicin, 
epirubicin, gemcitabine, immunostimulants, 
monoclonal antibodies, nivolumab, 
NY-ESO-1, other vaccines, pazopanib 
hydrochloride, sirolimus, sorafenib, 
temozolomide, and vaccines. D, Myxoid/
round cell liposarcoma: anticancer therapy 
(top 5 vs other) in second line. In second 
line, the single agents included in "Other 
single agent systemic therapy" category 
are atezolizumab, dacarbazine, dasatinib, 
gemcitabine, ifosfamide, olaratumab, 
pembrolizumab, protein kinase inhibitors, 
selumetinib, sorafenib, sunitinib, and 
vaccines
A
B
C
D
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the lung in 37.3% and 20.5% of patients, respectively. For 
MRCL, the most frequent sites of recurrence after first- 
and second-line therapy were soft tissue (54.8%) and lung 
(19.8%), respectively. The mean number of hospitalizations 
during first-line systemic anticancer therapy was 1.4 (stan-
dard deviation 1.19) for SS and 1.7 (standard deviation 1.79) 
for MRCL. The median number of blood transfusions during 
first-line systemic anticancer therapy was 1.5 (range: 1, 10) 
for patients with SS and 1.0 (range: 1, 2) for patients with 
MRCL.
Figure 4 shows survival outcomes for the top 5 regimens 
(with at least 25 patients) used for first-line systemic anti-
cancer therapy among patients with SS or MRCL. Among 
patients who received doxorubicin plus ifosfamide (the top 
first-line therapy), the 12, 24, and 36-month survival rates 
for patients with SS were 90.0% (95% CI, 81.7-94.7), 51.7% 
(95% CI, 40.5-61.8), and 32.5% (95% CI, 22.0-43.3) respec-
tively, and for patients with MRCL, 90.6% (95% CI, 73.6-
96.9), 59.6% (95% CI, 39.8-74.8), and 23.3% (9.1-41.2), 
respectively.
4 |  DISCUSSION
This retrospective study analyzed clinical outcomes of SS 
and MRCL patients treated with systemic anticancer therapy 
in routine clinical practice at major sarcoma care medical 
centers. Nine centers from across the United States were in-
cluded, and an exploratory analysis of clinical outcomes by 
center did not demonstrate significant differences for first- or 
second-line patients with SS or for second-line patients with 
MRCL. However, differences due to variation in number of 
patients included by site were seen for first-line patients with 
MRCL in 1 center (n = 2) that had a 54.4-month median OS 
and another center (n = 23) with 11.7 months.
The patients included in this study were older than the ex-
pected age for SS, which in most studies usually range from 
age 15 to 30 years old. The estimated median OS from the SS 
cohort from first-line treatment (n = 249) was 24.7 months 
(95% CI, 20.9-29.4) and the median PFS was 7.5  months 
(95% CI, 6.4-8.4). These survival outcomes appear greater 
than those published from previous retrospective series and 
clinical trials.3-8,22-24
One of the most recent studies that included a significant 
cohort of patients with locally advanced or metastatic SS 
(n = 313) reported a median OS of 15.0 months and a median 
PFS of 6.3 months.5 The proportion of patients with SS in our 
study who had metastases (85.1%) was comparable to that 
seen in the study by Vlenterie et al, but patients with metas-
tases in our study had a greater median OS vs the Vlenterie 
study (23.4 months vs 14.9 months). One of the few recent 
retrospective studies with only metastatic soft tissue sarcoma 
patients by Savina et al25 showed that the cohort of patients 
with SS (n = 188) had a reported OS of 19.7 months.
In this study's MRCL cohort, the median OS and median 
PFS from first-line treatment were 29.8  months (95% CI, 
27.0-44.6) and 8.9 months (95% CI 4.5-12.0), respectively. 
It is difficult to compare the outcomes for the MRCL cohort 
Disease type All patients
Locally advanced, 
unresectable Metastatic
  Median months (95% CI)
Synovial sarcoma N = 249 N = 37 N = 212
Overall survival 24.7 (20.9, 29.4) 33.8 (21.3, 49.1) 23.4 (19.9, 28.0)
Progression-free 
survival
7.5 (6.4, 8.4) 8.6 (6.4, 12.4) 7.5 (5.7, 8.3)
Time to next 
treatment
9.2 (7.9, 10.2) 10.1 (6.9, 22.0) 9.2 (7.9, 10.2)
Time to distant 
metastasis
21.8 (14.6, 32.6) 14.6 (10.3, 29.3) 27.1 (17.3, NR)
Myxoid/round cell 
liposarcoma
N = 101 N = 9 N = 92
Overall survival 29.9 (27, 44.6) NR (4.6, NR) 29.2 (26.2, 35.1)
Progression-free 
survival
8.9 (4.5, 12.0) 12.5 (1.4, 17.0) 8.0 (4.0, 11.5)
Time to next 
treatment
12.2 (7.3, 15.2) 27.1 (1.4, 70.8) 11.0 (6.4, 14.5)
Time to distant 
metastasis
17.0 (12.5, 52.4) 17.0 (6.9, NR) 17.5 (12.0, 52.4)
Abbreviations: CI, confidence interval; NR, not reached.
T A B L E  1  Survival and other clinical 
outcomes from start of first-line systemic 
anticancer therapy
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in this study to other data due to the small number of patients 
with MRCL in published studies.12,13,26,27 One of the most 
detailed studies on MRCL was a retrospective review of 268 
enrolled patients with localized or metastatic disease treated 
at the University of Texas MD Anderson Cancer Center be-
tween 1990 and 2010.7 Of these, 61 patients had metastatic 
disease and their disease-specific survival was 78% at 1 year 
and 8.2% at 5  years. None of the patients survived over 
9 years.
The survival outcomes in this study, when analyzed by 
systemic anticancer therapy, appear longer than in previously 
published data as well. In this study, most patients received 
systemic anticancer therapy per National Comprehensive 
Cancer Network guidelines for management of their subtype 
of soft tissue sarcoma. An important consideration is that 
there were systemic anticancer therapies not yet approved 
during the time for which data were abstracted, such as tra-
bectedin for the treatment of liposarcoma, which was not ap-
proved until October 2015.
In this study, the median OS for patients with SS in first-
line systemic anticancer therapy on doxorubicin plus ifosfamide 
(n = 93), single agent ifosfamide (n = 51), and single agent doxo-
rubicin (n = 24) was 24.5, 28.0, and 20.0 months, respectively. 
For patients with MRCL in first-line systemic anticancer ther-
apy, the median OS for doxorubicin plus ifosfamide (n = 33), 
single agent doxorubicin (n = 20), and single agent trabectedin 
(n = 8) was 27.8, 54.6, and 28.8 months, respectively.
Comparisons to outcomes for similar therapies in the pub-
lished literature are difficult due to the paucity of studies with 
more than 50 enrolled patients with SS or MRCL that reported 
F I G U R E  2  Synovial sarcoma: overall survival and baseline characteristics. Among the synovial sarcoma patients, location of the primary 
tumor, metastatic lesions at start of first-line therapy, metastatic resection performed, lymphocyte to neutrophil count, and albumin level appear 
to be prognostic for overall survival in this exploratory analysis. The #Events indicates the number of patients experiencing the event (ie, death) 
within each category and the #Total is the total number of patients in each category. Cat1, category 1; Cat2, category 2; Chemo, chemotherapy; CI, 
confidence interval; F, female; M, male; N, no; XRT, radiotherapy; Y, yes
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survival outcomes by systemic anticancer therapy. No studies 
to date with more than 50 enrolled patients with MRCL have 
reported outcomes with different anticancer therapies.
However, a standard systemic anticancer therapy for ad-
vanced soft tissue sarcoma is doxorubicin plus ifosfamide, 
which had a median OS of 14.3  months (12.5-16.5) and 
median PFS of 7.4  months (95% CI, 6.6.-8.3) in Judson 
et al (n  =  228).28 A systematic review of anticancer ther-
apy in SS identified only 1 study with greater than 50 pa-
tients with advanced SS who received therapies like those 
in this study.6 In the 2016 Vlenterie study, patients on the 
top three anticancer regimens—anthracyline-based treatment 
(n = 121), doxorubicin plus ifosfamide (n = 112), and ifosfa-
mide alone (n = 42)—had a median OS of 14.85, 14.98, and 
15.34 months, respectively.5
The use of registries is well validated for understanding 
clinical outcomes in patients with cancer and rare diseases 
such as SS and MRCL. Information on clinical outcomes, in-
cluding remission and death, can be obtained if the patients 
are followed routinely, either directly or with other registries 
or administrative databases.29 Retrospective registries are 
also a reliable and valuable complement to randomized clini-
cal trials in determining real world outcomes.30
A comparison of clinical outcomes in our study to the 
published data is also not possible, since the selection of 
treatment in this study was not determined by predefined eli-
gibility criteria. In addition, this study is limited by variation 
in real world practice between medical centers and the use 
of other types of anticancer therapy and locoregional proce-
dures, typically proscribed in a clinical trial. This study found 
F I G U R E  3  Myxoid/round cell liposarcoma: overall survival and baseline characteristics. For the patients with myxoid/round cell 
liposarcoma, stage at diagnosis, metastatic resection performed, and organs involved at start of first-line therapy appear to be prognostic for overall 
survival in this exploratory analysis. The #Events indicates the number of patients experiencing the event (ie, death) within each category and 
the #Total is the total number of patients in each category. Cat1, category 1; Cat2, category 2; Chemo, chemotherapy; CI, confidence interval; F, 
female; M, male; N, no; XRT, radiotherapy; Y, yes
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that a significant percent of patients received either metas-
tectomies or addition of radiation or other local therapy in 
the management of disease burden, which likely improved 
clinical outcomes.
Another consideration is that the eligibility criteria for this 
study were designed to ensure inclusion of only pathologically 
confirmed patients with SS or MRCL, who received at least 
1 line of systemic anticancer therapy and were followed until 
death or the last confirmed survival documented. This allowed 
for a more complete follow-up of survival than clinical trials in 
which patients who have discontinued investigational products 
are lost to follow-up or not followed until death. These factors 
likely contributed to the greater survival outcomes in this study.
The statistics gathered were broad and detailed, including 
TTNT and TTDM for all patients in the study; these variables 
were also compared in patients with locally advanced disease 
vs metastatic disease. This analysis indicated that the time to 
evidence of a new distant metastatic lesion was shortened for 
locally advanced/unresectable SS disease compared to pa-
tients with SS with metastatic disease. This was most likely 
due to the metastatic lesion not being discovered in body areas 
not included on imaging at initiation of first-line systemic 
anticancer therapy (median TTDM 14.6 vs 27.1 months for 
patients with SS with locally advanced and metastatic disease, 
respectively). Time to distant metastases among patients with 
MRCL with locally advanced/unresectable disease and meta-
static disease was 17 and 17.5 months, respectively.
Other sources of bias and confounding include the vari-
ation in clinical practice across the cancer centers. The nine 
centers in the study did not use the same methods for sys-
tematic collection of data in the medical records of patients 
with SS or MRCL. Nor were the same protocols used for es-
tablishing dosing schedules of the systemic anticancer ther-
apy. Treating oncologists varied in their selection of systemic 
anticancer therapy and locoregional therapy, the length of 
time to continue treatment, and when to initiate or discon-
tinue treatment after tumor progression. Response Evaluation 
Criteria in Solid Tumors (RECIST) v1.1 was not used as a 
measure of response nor were death certificates available, 
and thus verification was not performed. Death was docu-
mented from tumor registry updates and documentation in 
medical records, and sources were verified.
While just nine centers were involved in the study, all 
regions in the United States were represented, including the 
Northwest, West, Midwest, East, South, and Southeast. The 
variation in locale and the study's reliance on real-world out-
comes makes it more likely that the data are an accurate re-
flection of oncology practice today.
F I G U R E  4  Overall Survival and Progression-Free Survival by First-Line Therapy. This figure portrays overall survival and progression-free 
survival by the top five first-line therapies with more than 25 patients. The overall survival and progression-free survival rates for each subgroup at 
a given timepoint can be determined by visually tracing a vertical line from the timepoint on the X-axis to the line for the subgroup; that location 
of the subgroup line on the Y-axis indicates the rate. A, Overall survival in patients with synovial sarcoma by first-line therapy. B, Overall survival 
in patients with myxoid/round cell liposarcoma by first-line therapy. C, Progression-free survival in patients with synovial sarcoma by first-line 
therapy. D, Progression-free survival in patients with myxoid/round cell liposarcoma by first-line therapy
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5 |  CONCLUSION
This is the first large-scale systematic retrospective study 
including patients with locally advanced/unresectable or 
metastatic SS or MRCL. The survival outcomes in this study 
appear improved over previously published data. Thus, this 
study provides greater insight into SS and MRCL clinical 
outcomes than previously published studies and has the po-
tential to inform prognosis and treatment decisions, as well 
as provide guidance in the development of future therapeutic 
clinical trials.
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